Immunology

all catalysts(0)

nothing on the calendar yet

News(10)

• Kolon TissueGene cuts 37 US staffers after Phase 3 fail
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• She grew up unvaccinated. Now she’s a leading voice for science — and empathy
  Immunologist Liz Marnik, who grew up unvaccinated, says shaming people who distrust science will do nothing to improve vaccine acceptance.
  stat · 2d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 3d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 3d ago
• Biotech's reverse merger renaissance poised to continue
  A biotech collected $820 million in investor commitments this month to take its China-sourced immunology drug onto the public markets. That would make it one of the largest, if not the ...
  endpoints · 3d ago
• Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
  Evaxion has scrapped a next-gen solid tumor vaccine in order to channel resources to a candidate specifically targeting brain cancer.
  fiercebiotech · 4d ago
• ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
  BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.
  fiercebiotech · 7d ago
• STAT+: Eli Lilly targets booming black market for retatrutide
  Khartis raises oral immunology funds, Neurocrine drug safety concerns, and more biotech news from The Readout
  stat · 7d ago
• Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
  Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
  fiercebiotech · 8d ago
• Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
  Though it's no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that asset to two disease-controlling drugs it already discovered in-h…
  endpoints · 9d ago